Filing Details
- Accession Number:
- 0001225208-20-007628
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-05-13 18:28:49
- Reporting Period:
- 2020-05-11
- Accepted Time:
- 2020-05-13 18:28:49
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1099800 | Edwards Lifesciences Corp | EW | Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842) | 364316614 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1438538 | M. Catherine Szyman | One Edwards Way Irvine CA 92614 | Cvp, Critical Care | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-05-11 | 5,950 | $0.00 | 18,318 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-05-11 | 548 | $217.84 | 17,770 | No | 4 | F | Direct | |
Common Stock | Disposition | 2020-05-11 | 2,951 | $217.84 | 14,819 | No | 4 | F | Direct | |
Common Stock | Disposition | 2020-05-12 | 682 | $225.05 | 14,137 | No | 4 | F | Direct | |
Common Stock | Disposition | 2020-05-13 | 750 | $216.93 | 13,387 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | F | Direct | |
No | 4 | F | Direct | |
No | 4 | F | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Performance Rights | Disposition | 2020-05-11 | 5,950 | $0.00 | 5,950 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2020-05-11 | No | 4 | M | Direct |
Footnotes
- On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form.
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020.